A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy.

@article{Hunter2006AHP,
  title={A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy.},
  author={Chris Hunter and Raffaella Smith and Daniel P Cahill and P. Stephens and Claire E. Stevens and J. W. Teague and Chris Greenman and Sarah J Edkins and Graham Bignell and Helen Davies and Sarah O'meara and Adrian Bruce Parker and Tim Avis and Syd Barthorpe and Lisa Brackenbury and Gemma Buck and Adam Butler and Jody Clements and Jennifer Cole and Ed M. Dicks and Simon Forbes and Matthew John Gorton and Kristian A. Gray and Kelly A. Halliday and Rachel Harrison and Katy Hills and Jonathon Hinton and Andy Jenkinson and David Jones and Vivienne Kosmidou and Ross Laman and Richard H. Lugg and Andrew Menzies and Janet Elise. Perry and Robert E Petty and Keiran Raine and David Richardson and Rebecca Shepherd and Alexandra Joanne Small and Helen M. Solomon and Calli Tofts and Jennifer Varian and Sofie West and Sara Widaa and Andy Yates and Douglas F. Easton and Gregory J Riggins and Jennifer E. Roy and Kymberly K Levine and Wolf M{\"u}ller and Tracy T Batchelor and David N Louis and Michael R. Stratton and P. Andrew Futreal and Richard Wooster},
  journal={Cancer research},
  year={2006},
  volume={66 8},
  pages={
          3987-91
        }
}
Malignant gliomas have a very poor prognosis. The current standard of care for these cancers consists of extended adjuvant treatment with the alkylating agent temozolomide after surgical resection and radiotherapy. Although a statistically significant increase in survival has been reported with this regimen, nearly all gliomas recur and become insensitive to further treatment with this class of agents. We sequenced 500 kb of genomic DNA corresponding to the kinase domains of 518 protein kinases… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 163 CITATIONS

Whole Genome Sequencing-Based Discovery of Structural Variants in Glioblastoma.

  • Methods in molecular biology
  • 2018
VIEW 10 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Recent advances in the molecular understanding of glioblastoma

  • Journal of Neuro-Oncology
  • 2011
VIEW 6 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

The role of cytotoxic drugs in the treatment of central nervous system gliomas.

  • Acta neurologica Belgica
  • 2010
VIEW 2 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

FILTER CITATIONS BY YEAR

2006
2019

CITATION STATISTICS

  • 11 Highly Influenced Citations

  • Averaged 18 Citations per year over the last 3 years

References

Publications referenced by this paper.
SHOWING 1-10 OF 21 REFERENCES

Tissues of MSH2-deficient mice demonstrate hypermutability on exposure to a DNA methylating agent.

  • Proceedings of the National Academy of Sciences of the United States of America
  • 1998
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

A homozygous mutation in MSH6 causes Turcot syndrome.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2005
VIEW 1 EXCERPT

MGMT gene silencing and benefit from temozolomide in glioblastoma.

  • The New England journal of medicine
  • 2005
VIEW 2 EXCERPTS

Sequence survey of receptor tyrosine kinases reveals mutations in glioblastomas.

  • Proceedings of the National Academy of Sciences of the United States of America
  • 2005
VIEW 1 EXCERPT

Similar Papers

Loading similar papers…